PMID- 19326408
OWN - NLM
STAT- MEDLINE
DCOM- 20090625
LR  - 20090401
IS  - 1527-6473 (Electronic)
IS  - 1527-6465 (Linking)
VI  - 15
IP  - 4
DP  - 2009 Apr
TI  - Killer cell immunoglobulin-like receptor genotype and killer cell 
      immunoglobulin-like receptor-human leukocyte antigen C ligand compatibility 
      affect the severity of hepatitis C virus recurrence after liver transplantation.
PG  - 390-9
LID - 10.1002/lt.21673 [doi]
AB  - In 20% to 30% of infected individuals, hepatitis C virus (HCV) can cause 
      cirrhosis and hepatocellular carcinoma, for which liver transplantation is the 
      best treatment available. HCV re-infection is universal, and hepatitis disease 
      recurrence occurs in most cases with a 30% probability of progression to graft 
      cirrhosis at 5 years post-transplant. The immunological response to HCV involves 
      natural killer (NK) cells and killer cell immunoglobulin-like receptors (KIRs), 
      which specifically recognize human leukocyte antigen (HLA) class I antigens 
      present on target cells. The effector functions of NK cells are influenced by 
      inhibitory KIR interaction with self-HLA class I ligands, with HLA-C being the 
      most predominant. This study examines the roles of KIR genotypes and their HLA 
      ligands in both HCV disease recurrence and its progression. A total of 151 
      patients were included in the cohort, and their clinical details were recorded. 
      Liver biopsies were used to define the absence/presence of recurrent hepatitis, 
      the degree of fibrosis, and the progression to cirrhosis over a 10-year period. 
      Mismatching of KIR-HLA-C ligands between donor-recipient pairs was associated 
      with the recurrence of hepatitis (P = 0.008). The presence of KIR2DL3 in the 
      recipient correlated with progression to liver fibrosis (P = 0.04). The 
      mismatching of HLA-KIR ligands favored the progression of the recurrent hepatitis 
      to fibrosis only in the presence of KIR2DL3 (P = 0.04). These preliminary results 
      indicate that the KIR genotype and KIR-HLA-C ligand compatibility play roles in 
      the recurrence and progression of hepatitis C disease in liver transplant 
      recipients.
CI  - Copyright 2009 AASLD.
FAU - de Arias, Alejandro Espadas
AU  - de Arias AE
AD  - Department of Regenerative Medicine, Organ and Tissue Transplantation Immunology, 
      Ospedale Maggiore Policlinico, Mangiagalli, Regina Elena, Istituto di Ricovero e 
      Cura a Carattere Scientifico, Milan, Italy.
FAU - Haworth, Simone Elizabeth
AU  - Haworth SE
FAU - Belli, Luca Saverio
AU  - Belli LS
FAU - Burra, Patrizia
AU  - Burra P
FAU - Pinzello, Giovambattista
AU  - Pinzello G
FAU - Vangeli, Marcello
AU  - Vangeli M
FAU - Minola, Ernesto
AU  - Minola E
FAU - Guido, Maria
AU  - Guido M
FAU - Boccagni, Patrizia
AU  - Boccagni P
FAU - De Feo, Tullia Maria
AU  - De Feo TM
FAU - Torelli, Rosanna
AU  - Torelli R
FAU - Cardillo, Massimo
AU  - Cardillo M
FAU - Scalamogna, Mario
AU  - Scalamogna M
FAU - Poli, Francesca
AU  - Poli F
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Liver Transpl
JT  - Liver transplantation : official publication of the American Association for the 
      Study of Liver Diseases and the International Liver Transplantation Society
JID - 100909185
RN  - 0 (HLA-C Antigens)
RN  - 0 (KIR2DL3 protein, human)
RN  - 0 (Ligands)
RN  - 0 (Receptors, KIR)
RN  - 0 (Receptors, KIR2DL3)
SB  - IM
CIN - Liver Transpl. 2009 Apr;15(4):357-9. PMID: 19326413
MH  - Adult
MH  - Biopsy
MH  - Carcinoma, Hepatocellular/immunology/*surgery/virology
MH  - Disease Progression
MH  - Female
MH  - Gene Frequency
MH  - Genotype
MH  - Graft Rejection/immunology/virology
MH  - Graft Survival
MH  - HLA-C Antigens/*immunology
MH  - Hepatitis C, Chronic/*complications/immunology/surgery
MH  - Histocompatibility
MH  - Humans
MH  - Italy
MH  - Killer Cells, Natural/*immunology/virology
MH  - Ligands
MH  - Liver/immunology/pathology/virology
MH  - Liver Cirrhosis/immunology/*surgery/virology
MH  - Liver Neoplasms/immunology/*surgery/virology
MH  - *Liver Transplantation
MH  - Male
MH  - Middle Aged
MH  - Receptors, KIR/*genetics/immunology
MH  - Receptors, KIR2DL3/genetics
MH  - Recurrence
MH  - Retrospective Studies
MH  - Risk Assessment
MH  - Risk Factors
MH  - Severity of Illness Index
MH  - Time Factors
MH  - Transplantation, Homologous
MH  - Treatment Outcome
EDAT- 2009/03/28 09:00
MHDA- 2009/06/26 09:00
CRDT- 2009/03/28 09:00
PHST- 2009/03/28 09:00 [entrez]
PHST- 2009/03/28 09:00 [pubmed]
PHST- 2009/06/26 09:00 [medline]
AID - 10.1002/lt.21673 [doi]
PST - ppublish
SO  - Liver Transpl. 2009 Apr;15(4):390-9. doi: 10.1002/lt.21673.